(redirected from CSII)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia.

INFUSION, med. jur. A pharmaceutical operation, which consists in pouring a hot or cold fluid upon a substance, whose medical properties it is desired to extract. Infusion is also used for the product of this operation. Although infusion differs from decoction, (q.v.) they are said to be ejusdem generis; and in the case of an indictment which charged the prisoner with giving a decoction, and the evidence was that he had given an infusion, the difference was held to be immaterial. 8 Camp. R. 74.

A Law Dictionary, Adapted to the Constitution and Laws of the United States. By John Bouvier. Published 1856.
References in periodicals archive ?
In the univariate analysis, an association between HbA1c level (as a dependent variable) and age, %BI, years on CSII, and average number of blood glucose measurements per day was found.
CSII is one of the options for patients with diabetes requiring multiple daily insulin injections and wide fluctuations of blood glucose.
The following inclusion criteria were applied: availability of pre-pump clinical and biochemical data (insulin requirements, Hb[A.sub.1c] level, weight, and height) as well as complete follow-up data; CSII started based on the criteria of the Ministry of Health pump committee and followed-up in a government hospital (i.e.
All patients included in this study were on MDI (basal/bolus regimen) defined as four or more injections/day or CSII, both with flexible carbohydrate counting.
Treatment options for insulin-induced lipoatrophy include subcutaneous co-administration of corticosteroid with insulin (e.g., dexamethasone or betamethasone), low-dose oral corticosteroid (prednisone 5-10 mg daily) (8), changing between different insulin preparations (9), or changing the mode of insulin delivery (the use of CSII).
Modern CSII pumps (with Bolus Wizard calculators) have been around for a decade, yet we significantly underutilize them.
Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years.
The pooled results showed the artificial pancreas kept blood glucose levels in the normal range for 60percent of the time, compared with 40percent for the CSII. The artificial pancreas reduced the time by 50percent that blood glucose levels fell below 3.9mmol/l - the level considered as mild hypoglycaemia.
The first continuous subcutaneous insulin infusion (CSII) system was developed in the 1960s, with commercial use beginning in 1978.
* ** ** (CSII) (MF) Long Beach, CA Cooper Power Systems (DD) * * * Neptune, NJ Covington Power Services (DD) * * * Greensboro, NC Cummins Atlantic Inc.
Continuous subcutaneous insulin infusion (CSII) is a well known and successful method used in type 1 diabetic patients (7,8).